Study Stopped
This multicenter randomized controlled trial planned competitive enrollment across multiple sites; however, no patients were enrolled at one site. Only 44 of 202 participants were enrolled over four years, so early termination is proposed.
Early RRT in AKI After Cardiac Surgery
Early Application of Renal-Replacement Therapy in Patients With Acute Kidney Injury After Cardiac Surgery: A Multicenter Randomized Controlled Trial
1 other identifier
interventional
44
1 country
2
Brief Summary
Acute kidney injury (AKI) is one of the major complications after cardiac surgery that may affects 20% to 40% of patients according to the definitions. Also, AKI after cardiac surgery is associated with high morbidity and mortality, with eight-fold increase in the odds ratio of death when renal replacement therapy (RRT) is required. However the indication and the optimal timing of RRT initiation are still controversial. We hypothesized that a strategy of early initiation of RRT would result in a lower risk of surgical mortality than a standard strategy in post cardiac surgery patients with AKI of Kidney Disease: Improving Global Outcomes (KDIGO) classification stage 2 (serum creatinine, 2.0 times the baseline level; urine output, \<0.5mL/kg/h for 6 or more hours).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2021
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 10, 2021
CompletedStudy Start
First participant enrolled
December 24, 2021
CompletedFirst Posted
Study publicly available on registry
January 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 11, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 11, 2026
CompletedFebruary 12, 2026
February 1, 2026
4.1 years
December 10, 2021
February 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants with operative mortality
any death, regardless of cause, occurring (1) within 30 days after surgery in or out of the hospital, and (2) after 30 days during the same hospitalization subsequent to the operation
at postoperative 30 days
Secondary Outcomes (8)
Overall survival
at postoperative 90 days
Number of participants with cardiovascular mortality
at postoperative 90 days
Number of participants with renal replacement therapy dependency
at postoperative 90 days
Number of participants with major adverse kidney events (MAKE)
at postoperative 90 days
Number of participants with renal replacement therapy related morbidity
at postoperative 90 days
- +3 more secondary outcomes
Study Arms (2)
Early RRT group
EXPERIMENTALPatients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).
Delayed RRT group
ACTIVE COMPARATORPatients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.
Interventions
The best medical management continues until the patient meets absolute indication of renal replacement therapy
Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
Eligibility Criteria
You may qualify if:
- Patients within 7 days after cardiac surgery
- Acute kidney injury (AKI) described as Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (urine output \<0.5mL/kg/h for ≥6h or 2-fold increase in serum creatinine compared with baseline)
You may not qualify if:
- previous renal replacement therapy
- AKI secondary to obstructive nephropathy
- previous kidney transplantation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Seoul National University Bundang Hospital
Seongnam, South Korea
Seoul National University Hospital
Seoul, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ho Young Hwang, MD, PhD
Seoul National University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 10, 2021
First Posted
January 3, 2022
Study Start
December 24, 2021
Primary Completion
February 11, 2026
Study Completion
February 11, 2026
Last Updated
February 12, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
IPD will not be shared because it is not allowed by our institutional IRB.